Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the combination therapy of Toripalimab and axitinib or sunitinib monotherapy.

  • 0 views
  • 05 Feb, 2021
  • 1 location
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR- and -; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC

measurable disease
cancer chemotherapy
angiogenesis inhibitor
metastatic soft tissue sarcoma
soft tissue sarcoma
  • 1 views
  • 23 Jan, 2021
  • 1 location
Testing the Addition of a New Anti-cancer Drug Radium-223 Dichloride to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone the RadiCaL Study

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop …

platelet count
antineoplastic
metastasis
brain metastases
targeted therapy
  • 5 views
  • 03 Mar, 2021
  • 21 locations
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor Advanced Gynecological Tumors

with a small-molecule multikinase inhibitor Famitinib in subjects with advanced RCC/UC/CC/EC and recurrent OC. chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian

  • 0 views
  • 22 Jan, 2021
  • 1 location
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

nivolumab in patients with advanced RCC when given intermittently. Nivolumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer, non small cell

measurable disease
sunitinib
vaccine therapy
tivozanib
metastatic melanoma
  • 1 views
  • 26 Jan, 2021
  • 1 location
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

response and (3) DC migration in the organism Methodology: phase II trial in patients with advanced renal cell carcinoma and melanoma. We will perform repeated immunizations with DC loaded with

measurable disease
carcinoma
advanced renal cell carcinoma
solid tumour
metastatic melanoma
  • 35 views
  • 07 Nov, 2020
  • 1 location
Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma

. Increasing evidence suggests that response to immune checkpoint inhibitors (ICIs), a novel treatment for advanced RCC (aRCC) and other epithelial tumors, can be influenced by the patient gut microbiota

  • 0 views
  • 01 Mar, 2021
  • 2 locations
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

measurable disease
kinase inhibitor
metastasis
tumor cells
liver metastasis
  • 37 views
  • 03 Mar, 2021
  • 19 locations
CBM588 Nivolumab and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced). CBM588 is a probiotic that may help to increase the effect of immunotherapy. Immunotherapy …

measurable disease
pd-l1
metastasis
curative surgery
tumor cells
  • 38 views
  • 26 Jan, 2021
  • 1 location